Craig-Hallum bullish on Certara, initiates with a Buy

As previously reported, Craig-Hallum analyst Matthew Hewitt initiated coverage of Certara (CERT) with a Buy rating and $16 price target The firm likes the overlap of near-term prospects and its long-term economics. Moreover, Craig-Hallum views the company as being at the center of the pharma/biotech rebound, offering investors a unique opportunity to participate in the overall increase in R&D investment in the coming quarter/years. With shares currently trading at 14.3-times 2026EV/EBITDA, the firm believes the current valuation offers an attractive entry point for investors.